Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
PAXLOVID (COPACKAGED) (NIRMATRELVIR; RITONAVIR) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
PAXLOVID (COPACKAGED)
NDA
Get alerts
NIRMATRELVIR; RITONAVIR | N217188 | PFIZER INC
1 strength
2 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
2 unique patents, 2 exclusivities by expiration date
Active (2)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
11351149
Aug. 5, 2041
11541034
Oct. 31, 2041
D-195
Jan. 31, 2028
NCE
May. 25, 2028
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 150MG;100MG
RLD
2 patents
2 exclusivities
▴
TABLET;ORAL | Approved: May 25, 2023
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
11351149
Aug 5, 2041
—
Yes
Yes
U-3629
TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
—
11541034
Oct 31, 2041
—
—
—
U-3629
TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
—
Exclusivities (2)
Code
Date
Status
D-195
Jan 31, 2028
Active
NCE
May 25, 2028
Active